Promising results from Fate Therapeutics' ProHema Phase 1b trial on hematologic malignancies

Fate Therapeutics, Inc. announced today promising clinical results from a Phase 1b trial of ProHema (FT1050-enhanced umbilical cord blood) as part of double-umbilical cord blood (UCB) transplants in adult patients with hematologic malignancies who have undergone reduced-intensity conditioning therapy.  The data are being presented at the 53rd annual American Society of Hematology (ASH) meeting, being held December 10-13, in San Diego, California (Abstract Number: 653; entitled, "FT1050 (16,16-dimethyl Prostaglandin E2)-Enhanced Umbilical Cord Blood Accelerates Hematopoietic Engraftment After Reduced Intensity Conditioning and Double Umbilical Cord Blood Transplantation"). ProHema is a first-in-class therapeutic candidate, consisting of pharmacologically-enhanced hematopoietic stem cells (HSC), designed to improve HSC support during the normal course of a stem cell transplant for the treatment of patients with hematologic malignancies.

The Phase 1b double-UCB study conducted at the Dana-Farber Cancer Institute and the Massachusetts General Hospital achieved its primary objective of demonstrating safety and tolerability of ProHema based upon patient engraftment by Day 42 with greater than 5% chimerism of the ProHema unit. In addition, of the twelve subjects presented in the abstract that received a ProHema unit and an untreated unit, the median time to neutrophil recovery (> 500 cells/uL) was 17.5 days, which compares favorably to a median of 21 days for a historic control group of similarly treated subjects at the Dana-Farber Cancer Institute.

"These clinical trial data support Fate's novel therapeutic approach for the development of stem cell biology-based medicines," said Pratik Multani, M.D., Senior Vice President, Clinical Development at Fate Therapeutics. "We believe these clinical observations represent the first evidence that the ex vivo pharmacologic modulation of hematopoietic stem cells has the potential to improve patient outcomes, and we look forward to rapidly advancing ProHema into broader clinical investigation."

There were no instances of primary or secondary graft failure in the twelve subjects. The adverse events associated with the infusion of the ProHema unit appeared to be no greater than the background expected rate associated with cord blood infusion. The events consisted of five Grade 1/2 infusion-related events of chills, flushing, abdominal pain, or cough in 4 subjects.  In addition, one subject experienced transient Grade 4 ST-elevation following infusion and evidence of myocardial ischemia by cardiac troponin assay. To date, two cases of Grade 2 acute graft-versus-host disease (GvHD) have been observed in the first 100 days, and one subject developed NIH mild chronic GvHD.  Currently, treatment related mortality is 8% (one subject). One subject has relapsed, while the remaining ten subjects are alive without relapse with a median follow-up of approximately 8.5 months.

"ProHema appears to offer the potential to improve clinical outcomes for patients undergoing double-UCB transplantation," said Corey Cutler M.D., M.P.H., F.R.C.P.C., associate professor of medicine at the Dana-Farber Cancer Institute and Harvard Medical School and principal investigator of the Phase 1b clinical study. "Given the competitive engraftment dynamic of double-UCB transplantation, the clinical data suggest that the ProHema unit was able to preferentially engraft over the untreated cord blood unit. While further investigation is needed to confirm this finding, these data open the possibility for clinicians to treat the best-matched unit to encourage more favorable patient outcomes."


Fate Therapeutics, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
You might also like... ×
Advanced BioMatrix acquires HyStem products for R&D market